Drug intelligence / Profile preview

Shahvit-9G

Development stage: Unknown
Lead developer: SBM Enterprises
Modality: Small Molecules
Administration: Oral

Overview

Shahvit-9G is a finished pharmaceutical formulation developed and marketed by SBM Enterprises (SBM Pharmaceuticals), an Indian pharmaceutical company. It is described as a combination anti-inflammatory and enzyme preparation, often utilized as a multi-ingredient nutritional supplement. The "9G" nomenclature typically signifies a blend of nine herbal extracts (such as Ginseng, Ginkgo Biloba, and Green Tea Extract) combined with vitamins, minerals, and antioxidants. It is supplied in blister packs and is part of SBM's approved product portfolio for general health maintenance and the management of inflammatory conditions.

Brand names: Shahvit-9GShahvit9GShahvit 9G
Other names: Shahvit

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Shahvit-9G.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shahvit-9G.

Explore the full profile